NCT00343785View on ClinicalTrials.gov

Cyclophosphamide and Anti-thymocyte Globulin Followed By Methotrexate and Cyclosporine in Preventing Chronic Graft-Versus-Host Disease in Patients With Severe Aplastic Anemia Undergoing Donor Bone Marrow Transplant

PHASE2CompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

February 28, 2006

Primary Completion Date

May 31, 2012

Study Completion Date

August 31, 2012

Conditions
Aplastic Anemia
Interventions
DRUG

cyclophosphamide

Given IV

BIOLOGICAL

anti-thymocyte globulin

Given IV

DRUG

cyclosporine

Given IV or PO

PROCEDURE

allogeneic bone marrow transplantation

Undergo allogeneic bone marrow transplantation

DRUG

methotrexate

Given IV

GENETIC

DNA analysis

Correlative studies

OTHER

flow cytometry

Correlative studies

GENETIC

polymorphism analysis

Correlative studies

OTHER

laboratory biomarker analysis

Correlative studies

Trial Locations (3)

53226

Froedtert and the Medical College of Wisconsin, Milwaukee

84112

Huntsman Cancer Institute/University of Utah, Salt Lake City

98109

Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle

All Listed Sponsors
collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

lead

Fred Hutchinson Cancer Center

OTHER

NCT00343785 - Cyclophosphamide and Anti-thymocyte Globulin Followed By Methotrexate and Cyclosporine in Preventing Chronic Graft-Versus-Host Disease in Patients With Severe Aplastic Anemia Undergoing Donor Bone Marrow Transplant | Biotech Hunter | Biotech Hunter